February 18, 2025
Pancreatic cancer remains one of the most challenging cancers to diagnose early, with almost half of patients presenting with metastatic disease. Now, a growing body of […]
February 17, 2025
TOPLINE: Patients who experienced acute genitourinary and gastrointestinal toxicities following prostate cancer radiotherapy (RT) were more likely to have late toxicities and to experience declines in […]
February 14, 2025
The US Food and Drug Administration has approved vimseltinib (Romvimza, Deciphera Pharmaceuticals, LLC) to treat adult patients with symptomatic tenosynovial giant cell tumors (TGCT) who will […]
February 14, 2025
Adding talazoparib to enzalutamide led to a statistically significant and clinically meaningful improvement in overall survival in patients with metastatic castration-resistant prostate cancer compared with treatment […]
February 14, 2025
Among more than 3000 men from low-income communities who were screened for various health issues at mobile clinics, one had stage IV and none had metastatic […]
February 13, 2025
TOPLINE: Among breast cancer survivors who became pregnant, 34% resumed endocrine therapy (ET) by 2 years postdelivery, with a 19% cumulative incidence of subsequent breast cancer […]
February 13, 2025
TOPLINE: Cabozantinib improves progression-free survival (PFS) in patients with advanced extrapancreatic neuroendocrine tumors and pancreatic neuroendocrine tumors compared with placebo. METHODOLOGY: Cabozantinib, an oral small-molecule inhibitor […]
February 13, 2025
When Erin Reardon, MD, started the doxorubicin phase of her neoadjuvant chemotherapy, she was already convinced she had crossed the threshold into overtreatment for her stage […]
February 12, 2025
The US Food and Drug Administration (FDA) has approved a supplemental Biologics License Application for brentuximab vedotin (Adcetris; Seagen, Inc., a Pfizer subsidiary), in combination with […]